Aviva’s Iovance Biotherapeutics IOVA Stock Holding History

Aviva’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-40,108	Closed	-$1.27M	–	919
2021 Q1	$1.27M	Buy	+40,108	New	+$1.66M	0.01%	762

Other funds holding IOVA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Aviva's IOVA Position: Q2 2021 in Review

Aviva sold out of Iovance Biotherapeutics (IOVA) in Q2 2021, closing a stake of 40,108 shares — an estimated $1.27M sold.

Aviva first reported a position in IOVA in Q1 2021 and held it in 1 quarter. The position peaked at $1.27M in Q1 2021. 234 funds tracked by Wall St. Rank hold IOVA as of Q2 2021.

Aviva reported no remaining Iovance Biotherapeutics position as of Q2 2021 after selling out during the quarter.
Aviva sold 40,108 Iovance Biotherapeutics shares in Q2 2021, an estimated $1.27M.
Aviva first reported a position in Iovance Biotherapeutics in Q1 2021 and held it in 1 quarter.
Aviva's Iovance Biotherapeutics position peaked at $1.27M in Q1 2021.
234 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2021.

Based on Aviva's 13F filing for Q2 2021, filed 10 Aug 2021.